Viewing nowLyrica Capsules 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
Korea Hyutecs Pharmaceutical Co., Ltd.

MFDS item code 201905364 · Approved 2019.07.29 · Insurance code 649104530
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is effective in relieving peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy patients, helping to control symptoms. Additionally, it is utilized for the treatment of fibromyalgia, contributing to the improvement of muscle pain and fatigue. Thus, it is used for the alleviation and treatment of symptoms related to various neurological disorders.
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose is 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose is 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose is 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after every 4 hours of hemodialysis. [Table 1] Pregabalin dosage based on renal function ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older patients with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so careful observation for depression or mood changes is required during treatment. It should not be taken if allergic to pregabalin or its ingredients. Patients with certain genetic disorders such as lactose intolerance should also avoid this medication. Diabetic patients may require dose adjustments as weight gain could affect blood sugar control. If symptoms of angioedema occur, use should be discontinued immediately, and elderly patients with severe dizziness or drowsiness should be especially cautious. Blurry vision or changes in eyesight may occur, and if these symptoms appear, consultation with a doctor is necessary. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headaches, nausea, and anxiety; therefore, it should be tapered off slowly under a physician's guidance. Patients with a history of substance abuse may be at higher risk of misuse of this medication and should use it cautiously. Patients with pre-existing heart conditions or impaired renal function require careful monitoring and may need dosage adjustments. Caution should be exercised when co-administering with opioids, as the risk of central nervous system depression may increase. During pregnancy, especially in the first trimester, effects on the fetus are possible; therefore, women who are pregnant or planning to become pregnant should consult a doctor and use effective contraception. Women who are breastfeeding should consider discontinuing breastfeeding or consulting a doctor, as this medication can pass into breast milk. Care should be given to activities that require alertness, such as driving or operating machinery, as this medication may cause dizziness or drowsiness. In case of overdose, symptoms may include confusion, drowsiness, and depression, necessitating immediate medical attention; blood dialysis may be required if necessary. This medication should be kept out of reach of children and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is best stored at room temperature between 15 and 30 degrees Celsius, avoiding extreme heat or cold.
Hard capsule with a light yellow upper part and white lower part containing white powder
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
Korea Hyutecs Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.